Core Viewpoint - Changchun High-tech's subsidiary, Gensci Pharmaceutical, has received approval from the National Medical Products Administration for the clinical trial application of GenSci145 tablets, a new selective PI3Kα inhibitor aimed at treating advanced solid tumors with PIK3CA mutations [1][2]. Group 1: Clinical Development - GenSci145 is designed to target PIK3CA mutations, which are present in up to 40% of HR+/HER2- primary and metastatic breast cancer cases, providing a new treatment option for patients who have developed resistance to current therapies [1][2]. - Early-stage PI3Kα inhibitors have shown significant improvements in progression-free survival (PFS) but have limitations due to toxicity and impact on long-term treatment adherence, highlighting the need for new generation inhibitors like GenSci145 [2]. Group 2: Business Strategy and Market Position - The successful progression of the clinical trial for GenSci145 is expected to enhance the company's business structure, optimize product offerings, and strengthen its core competitiveness in the pharmaceutical industry [3]. - Changchun High-tech has been actively adjusting its strategy and increasing innovation investments, developing multiple core technology platforms with independent intellectual property rights, covering the entire process of innovative drug design, screening, evaluation, and formulation research [3]. - The company is focusing on high-demand therapeutic areas, particularly in endocrine metabolism and pediatric fields, to support sustainable development and diversification goals [3]. Group 3: Recent Developments - Recently, Gensci Pharmaceutical has disclosed multiple advancements in its drug development pipeline, including the approval of clinical trials for GenSci142 capsules and GS3-007a, both targeting specific medical conditions [4]. - The company has also received approval for GenSci140, a novel targeted antibody-drug conjugate for the treatment of advanced solid tumors, further expanding its product portfolio [4].

Core Viewpoint - China Resources Double Crane Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Beijing Double Crane Run Chuang Technology Co., Ltd., received the clinical trial approval notice for the drug DC6001, which is intended for the treatment of Stargardt disease in adolescents [1][3]. Group 1: Drug Approval and Development - The drug DC6001 is aimed at treating Stargardt disease, a hereditary macular degeneration condition in adolescents [1]. - The clinical trial application for DC6001 was submitted to the National Medical Products Administration (NMPA) on October 9, 2025, and the approval notice was received on December 19, 2025 [1]. Group 2: Financial Investment - The total research and development investment for the drug DC6001 has reached approximately RMB 14.897 million (unaudited) as of the date of the announcement [2]. Group 3: Future Steps and Obligations - The company will actively promote the research and development project in accordance with national regulations and will fulfill its information disclosure obligations regarding subsequent progress [4].

近日，北京义翘神州科技股份有限公司(以下简称：义翘神州)获得Scientist.com平台颁发的"2025年度供 应商绩效认可奖"(2025 Supplier Performance Recognition Award)，旨在表彰义翘神州在推动全球药物发 现研究方面做出的杰出贡献和卓越表现。 义翘神州通过哺乳动物细胞、杆状病毒-昆虫细胞、大肠杆菌及无细胞表达(CFPS)四大系统，为您提供 从基因合成到蛋白表达、纯化的一站式服务，是您定制重组蛋白表达的理想合作伙伴。义翘神州构建的 杂交瘤、Beacon®、流式单B、噬菌体和兔多抗技术五大抗体发现平台，成功开发30000+抗体，与很多 国际制药企业建立了良好的合作关系。 义翘神州美国公司首席商务官Rob Burgess表示： "我们深感荣幸能够获得Scientist.com的认可与肯定。也为双方长期而富有成效的合作深感自豪。这一奖 项充分彰显了我们团队致力于为全球科学界提供可靠、及时、创新解决方案的坚定承诺。未来，我们将 继续致力于赋能科研人员，为生命科学研究的进步贡献更大力量。" Scientist.com是全球大型的智能化生命科学研发采购平台，整合6000多家 ...

香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 的 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 對因 本 公 告全 部 或 任 何 部份 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致的 任 何 損 失承 擔任何責任。 Sirnaomics Ltd. 聖 諾 醫 藥 * （ 於開曼群島註冊成立之有限公司） （股份代號：2257） 自願性公告 業務更新 – 1 – 本 公 告 乃 由 本 公 司 自 願 作 出 。 概 不 保 證 本 公 司 將 能 成 功 開 發 或 最 終 將 STP 707成功商業化。本公司股東及潛在投資者於買賣本公司股份時應審慎 及謹慎行事。 承董事會命 Sirnaomics Ltd. 主席兼執行董事 潘洪輝 香港，2025年12月22日 於 本 公 告 日 期 ， 董 事 會 包 括 執 行 董 事 潘 洪 輝 博 士 、 非 執 行 董 事 歐 陽 雲 龍 先 生 及殷 惠 軍 博 士 ，以 及 獨 立 非執 行 董 事 王 宇山 先 生 、 ...

Core Viewpoint - Heng Rui Medicine (600276) has received approval from the National Medical Products Administration for clinical trials of SHR-9539 injection and HRS-3738 tablets, marking a significant step in its drug development pipeline [1] Group 1: SHR-9539 Injection - SHR-9539 injection is a Class 1 therapeutic biological product that targets multiple myeloma cells by recruiting and activating T cells [1] - Currently, there are no similar drugs approved for market in China [1] - The cumulative R&D investment for the SHR-9539 injection project is approximately 39.93 million yuan [1] Group 2: HRS-3738 Tablets - HRS-3738 tablets are a next-generation CRBNE3 ubiquitin ligase modulator that affects the proliferation of hematological tumor cells by degrading specific substrates [1] - The drug has strong substrate degradation capabilities and potential advantages in overcoming drug resistance [1] - There are no similar drugs approved for market domestically or internationally [1] - The cumulative R&D investment for the HRS-3738 tablet project is approximately 63.63 million yuan [1]

据悉，醋酸亮丙瑞林是 GnRH 类似物，用于治疗前列腺癌。塬研产品 LEUPLIN Pro 由武田药品工业株 式会社开发，2015 年 11 月获日本 PMDA 批准上市，尚未在国内上市。本品用法用量与中国已上市的 注射用亮丙瑞林微球不同，属仿制境外已上市但境内未上市的原研药品。截至目前，注射用醋酸亮丙瑞 林微球相关项目累计研发投入约 2,468 万元。 恒瑞医药（600276）(01276)公布，近日，公司子公司上海恒瑞医药有限公司收到国家药品监督管理局 核准签发关于注射用醋酸亮丙瑞林微球的《药物临床试验批准通知书》，将于近期开展临床试验。 ...

Core Viewpoint - The announcement indicates that the subsidiary Beijing Shengdi Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial of SHR-2906 injection, a self-developed therapeutic biological product aimed at weight control and metabolic regulation [1] Group 1: Product Development - SHR-2906 injection is expected to have a synergistic effect in reducing energy intake and promoting energy expenditure, thereby regulating glucose and lipid metabolism and controlling weight [1] - The product aims to improve the metabolic environment in the body and is anticipated to demonstrate clinical efficacy in treating overweight and obesity [1] - Currently, there are no similar drugs approved for market release domestically or internationally [1] Group 2: Financial Investment - The cumulative research and development investment for the SHR-2906 injection project has reached approximately 17.06 million yuan [1]

Core Viewpoint - The announcement highlights that Yabao Pharmaceutical's subsidiary has received approval for clinical trials of GLX002, a new drug aimed at treating pulmonary arterial hypertension (PAH) [1][2]. Group 1: Drug Information - Drug Name: GLX002 [2] - Dosage Form: Tablet [2] - Registration Category: Class 2.2 Chemical Drug [2] - Applicant: Beijing Yabao Biological Pharmaceutical Co., Ltd. [2] - Acceptance Number: CXHL2501089 [2] - Approval Conclusion: The drug meets the requirements for registration and is approved for clinical trials for PAH treatment [1][2]. Group 2: Drug Development and Market Context - GLX002 is a modified new drug based on bosentan dispersible tablets, targeting PAH in patients aged 1 and older [2]. - The drug aims to improve pulmonary vascular resistance (PVR) and enhance exercise capacity in both pediatric and adult patients with WHO functional class II-IV PAH [2]. - In 2024, the sales amount for bosentan dispersible tablets in China is projected to be approximately 20.32 million RMB, with public medical market sales around 17.61 million RMB and retail pharmacy sales about 2.71 million RMB [2]. - Currently, there are no other modified new drugs based on bosentan dispersible tablets available in the domestic or international markets [2]. Group 3: R&D Investment - As of the announcement date, the company has invested approximately 1.6343 million RMB in the R&D of the GLX002 project [3]. - The drug must undergo clinical trials and receive approval from the National Medical Products Administration before it can be manufactured and marketed [3].

传统新药研发平均耗时10-15年，花费超过20亿美元，而失败率高达95%。其根本原因在于，我们一直未能精准分析药物、靶点与机体之间的三重相互作用。面对这一困境，李翛然讲述了自己团队将AI技术与量子计算相结合，构建了“Quantum AIDD”（量子计算+AI药物设计）平台，通过高效求解薛定谔方程，提升药物分子模拟的精度和速度，推动定制化药物设计的故事。 李翛然博⼠是量子计算与AI制药领域的创新先锋，医图⽣科创始⼈兼CEO，CCF会员。他在量子计算和药物研发领域深耕，发表多篇SCI论⽂，拥有数项药物发明全球专利。作为业内先行者；主导医图⽣科的研发与商业化，开展了AI与量子计算在⽣物医药中的研究及应⽤项⽬。他将量子计算融⼊药物设计流程，探索未曾被AI与人类观察到的生物现象，开启“量⼦AI药物设计”时代，为制药⾏业带来全新的变革路径。 This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at https://ww ...

Core Viewpoint - Pfizer (PFE.US) is facing stagnant sales growth as it attempts to revamp its drug portfolio through costly acquisitions, with projected revenues for 2026 expected to be between $59.5 billion and $62.5 billion, aligning with Wall Street expectations [1] Group 1: Financial Projections - Pfizer anticipates minimal to no sales growth for the upcoming year, with expected sales of $62 billion for the current year, consistent with previous guidance [1] - The company forecasts adjusted earnings per share for next year to be between $2.80 and $3.00 [1] - Revenue from COVID-related products is projected to decline by approximately $1.5 billion to $5 billion next year [1] Group 2: Cost-Cutting Measures - Pfizer plans to implement significant cost-cutting measures, aiming to save over $7 billion by 2027, with most savings expected to be realized in the coming year [1] - The company intends to reinvest $500 million of the savings into research and development [2] Group 3: Acquisitions and Competition - Pfizer has recently acquired Metsera for $10 billion to enhance its drug pipeline in the obesity treatment sector, although the drugs are still in early development stages [2] - The company is also facing increased competition for key products like the pneumonia vaccine Prevnar and the heart disease treatment Vyndaqel [2] - Previous acquisitions, including a $43 billion deal for cancer drug maker Seagen, have not yet yielded sufficient success, with analysts predicting flat or declining sales at least until 2031 [3]